FDA approved aminolevulinic acid hydrochloride, known as ALA HCl (Gleolan, NX Development Corp.) as an optical imaging agent indicated in patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. June 6, 2017. More Information: https://www.fda.gov/Drugs/
sábado, 10 de junio de 2017
Aminolevulinic acid hydrochloride, known as ALA HCl (Gleolan, NX Development Corp.) as an optical imaging agent indicated in patients with gliomas
Approved Drugs > Hematology/Oncology (Cancer) Approvals & Safety Notifications
FDA approved aminolevulinic acid hydrochloride, known as ALA HCl (Gleolan, NX Development Corp.) as an optical imaging agent indicated in patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. June 6, 2017. More Information: https://www.fda.gov/Drugs/ InformationOnDrugs/ ApprovedDrugs/ucm279174.htm
FDA approved aminolevulinic acid hydrochloride, known as ALA HCl (Gleolan, NX Development Corp.) as an optical imaging agent indicated in patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery. June 6, 2017. More Information: https://www.fda.gov/Drugs/
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario